Cellular Immunotherapy Market - Global Forecast 2025-2032

The cellular immunotherapy market is rapidly evolving, with continuous scientific and operational advancements shaping a new era in precision cancer care. Key players are leveraging unique technologies and strategic collaborations to drive innovation and market growth.

Market Snapshot: Cellular Immunotherapy Market Growth Drivers

The Cellular Immunotherapy Market grew from USD 11.89 billion in 2024 to USD 13.29 billion in 2025. It is expected to continue growing at a CAGR of 12.34%, reaching USD 30.18 billion by 2032. This trajectory is powered by broad investment in next-generation therapies and emerging manufacturing efficiencies, underscoring the widening clinical impact of this field across hematologic and solid tumor indications.

Scope & Segmentation

This report delivers a granular analysis, forecasting cellular immunotherapy revenues by therapy, technology, indication, institution, and geography. The scope incorporates coverage of leading companies, regulatory shifts, investment patterns, and technological breakthroughs.

• Therapeutic Modalities: CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, T-Cell Receptor Therapy, Tumor-Infiltrating Lymphocytes Therapy
• Technology Spectrum: Cytokines & Immunomodulators, Monoclonal Antibodies
• Primary Indications: B-Cell Malignancies, Liver Cancer, Prostate Cancer, Renal Cell Carcinoma
• Institutional Categories: Academic Institutes, Biotech & Pharmaceutical Companies, Contract Organizations, Hospitals, Research Institutes
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Key Companies Reviewed: Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bellicum Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc.

Key Takeaways

• Precision and next-generation therapeutic platforms are strengthening the specificity of immune cell engineering, offering more durable oncology outcomes.
• Integration of artificial intelligence and advanced analytics is facilitating candidate optimization, risk prediction, and streamlined clinical workflows.
• Allogeneic and modular manufacturing platforms are expanding access and standardizing product quality for broader patient cohorts.
• Industry-academic consortia and cross-border collaborations are propelling translational pipelines, shortening the cycle from discovery to clinical adoption.
• Regional differences in infrastructure and policy are shaping unique market entry and adoption patterns worldwide, highlighting the need for tailored market strategies.

Tariff Impact: Navigating Supply Chain and Compliance Shifts

New United States tariffs on essential raw materials and consumables for cellular therapy production are adding complexity to supply chains and input costs. Companies are responding with supplier diversification, vertical integration, and regional stockpiling while regulators offer expedited review for domestic expansions. Ensuring robust quality and uninterrupted workflow now requires adaptive procurement and operational strategies.

Methodology & Data Sources

This research integrates systematic literature reviews, regulatory analyses, and primary interviews with industry leaders and stakeholders. Quantitative and qualitative inputs are cross-validated through proprietary and public datasets, enabling a balanced perspective on innovation, clinical outcomes, and market readiness.

Why This Report Matters

• Enables senior leaders to benchmark emerging technologies, institutional models, and geographic growth patterns for precise investment decisions.
• Offers actionable intelligence on operational challenges—including tariff impacts, scale-up solutions, and quality frameworks—that directly affect go-to-market success.

Conclusion

Cellular immunotherapy is poised to transform oncology, offering targeted solutions for both hematologic and solid tumors. Executives armed with this report will be better positioned to lead, innovate, and capture growth opportunities in an increasingly complex and competitive global landscape.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.